Ventavis(Iloprost) ( DrugBank: Iloprost )


1 disease
IDDisease name (Link within this page)Number of trials
86Pulmonary arterial hypertension1

86. Pulmonary arterial hypertension


Clinical trials : 1,181 Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-002803-42-AT
(EUCTR)
05/03/200820/02/2008Inhaled Iloprost for patients with pulmonary arterial hypertension and right heart failure:a pilot feasibility trialInhaled Iloprost for patients with pulmonary arterial hypertension and right heart failure:a pilot feasibility trial Pulmonary arterial hypertension (PAH) is associated with poor prognosis.The most common cause of death is right heart failure. The fact that right heart failure is associated with low systemic perfusion pressures limits the systemic use of potent vasodilators in this patient population. As a consequence, no therapeutic recommendations exist for patients experiencing right heart failure in the course of PAH.Trade Name: Ventavis(Iloprost)
Product Name: Ventavis(Iloprost)
Univ.Clinic of Internal Medicine II, Department of Cardiology, Medical University of Vienna, AustriaNULLNot RecruitingFemale: yes
Male: yes
8Austria